Geron Corporation Market Cap ($596.92 Million)
Market Cap & Net Worth: Geron Corporation (GERN)
Geron Corporation market cap. Geron Corporation (NASDAQ:GERN) has a market capitalization of $596.92 Million ($596.92 Million) as of November 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #11001 globally and #2885 in its home market, demonstrating a -17.04% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Geron Corporation's stock price $0.93 by its total outstanding shares 642473409 (642.47 Million). Also see Geron Corporation cash conversion from operations for how efficiently the company converts equity into cash flow.
Geron Corporation Market Cap History (2015–2026)
Geron Corporation market cap history from 2015 to 2026. Data shows change from $3.11 Billion to $596.92 Million (-10.79% CAGR). Check Geron Corporation share price for real-time trading data and today's change.
Index Memberships
Geron Corporation is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.60 Trillion | 0.02% | #301 of 976 |
|
NASDAQ Composite
IXIC
|
$39.84 Trillion | 0.00% | #1125 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.83 Trillion | 0.03% | #176 of 263 |
Weight: Geron Corporation's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Geron Corporation Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Geron Corporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore GERN net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
4.61x
Geron Corporation's market cap is 4.61 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.33 Billion | $6.16 Million | -$29.54 Million | 215.83x | N/A |
| 2017 | $1.16 Billion | $1.06 Million | -$27.92 Million | 1085.87x | N/A |
| 2018 | $642.47 Million | $1.07 Million | -$27.02 Million | 602.70x | N/A |
| 2019 | $873.76 Million | $460.00K | -$63.55 Million | 1899.49x | N/A |
| 2020 | $1.02 Billion | $253.00K | -$75.62 Million | 4037.68x | N/A |
| 2021 | $783.82 Million | $1.39 Million | -$116.11 Million | 562.68x | N/A |
| 2022 | $1.55 Billion | $596.00K | -$141.90 Million | 2608.70x | N/A |
| 2023 | $1.36 Billion | $237.00K | -$184.13 Million | 5719.91x | N/A |
| 2024 | $2.27 Billion | $76.99 Million | -$174.57 Million | 29.54x | N/A |
| 2025 | $848.06 Million | $183.88 Million | -$85.78 Million | 4.61x | N/A |
Competitor Companies of GERN by Market Capitalization
Companies near Geron Corporation in the global market cap rankings as of November 3, 2026. Also see how large is Geron Corporation's balance sheet for a full breakdown of the balance sheet.
Key companies related to Geron Corporation by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of Geron Corporation (2015–2026)
Market capitalization of Geron Corporation from 2015 to today. Between 2015 and today, Geron Corporation's market cap moved from $3.11 Billion to $ 596.92 Million, with a yearly change of -10.79%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $596.92 Million | -29.61% |
| 2025 | $848.06 Million | -62.71% |
| 2024 | $2.27 Billion | +67.77% |
| 2023 | $1.36 Billion | -12.81% |
| 2022 | $1.55 Billion | +98.36% |
| 2021 | $783.82 Million | -23.27% |
| 2020 | $1.02 Billion | +16.91% |
| 2019 | $873.76 Million | +36.00% |
| 2018 | $642.47 Million | -44.44% |
| 2017 | $1.16 Billion | -13.04% |
| 2016 | $1.33 Billion | -57.23% |
| 2015 | $3.11 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Geron Corporation was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $596.92 Million USD |
| MoneyControl | $596.92 Million USD |
| MarketWatch | $596.92 Million USD |
| marketcap.company | $596.92 Million USD |
| Reuters | $596.92 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Geron Corporation
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lowe… Read more